Notification of transaction by PDMR

RNS Number : 6209P

Celadon Pharmaceuticals PLC

10 February 2023

 

Celadon Pharmaceuticals Plc

("Celadon" or the "Company")

Notification of transactions by persons discharging managerial responsibility

London, 10 February 2023 - Celadon Pharmaceuticals Plc (AIM: CEL) , a UK-based pharmaceutical company focused on the research, cultivation, manufacturing and sale of breakthrough cannabis-based medicines, announces that an award of options to acquire the Company's shares for their nominal value of £0.01 was granted to an Executive Director on 9 February 2023 under the Company's Long Term Incentive Plan ("LTIP") as shown below.  The Options will vest on the third anniversary of grant on 9 February 2026, subject to the achievement of performance criteria.  Once vested, the awards must be held for two years.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Jonathan Turner
2	Reason for the notification
a)	Position / status	PDMR - Chief Financial Officer
b)	Initial notification / Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Celadon Pharmaceuticals plc
b)	LEI	213800YXCATORT475807
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of £0.01 GB00BDQYGP38
b)	Nature of the transaction	Award over nominal cost options under the Celadon Pharmaceuticals plc Long Term Incentive Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) £0.01 347,312 (under the LTIP)
d)	Aggregated information -  Aggregated volume -  Price	N/A Single Transaction
e)	Date of the transaction	9 February 2023
f)	Place of the transaction	London

Enquiries:

Celadon Pharmaceuticals Plc
James Short Jonathan Turner Arthur Wakeley	Via Powerscourt
Canaccord Genuity Limited (Nominated Adviser and Broker)
Bobbie Hilliam / Andrew Potts / Patrick Dolaghan	[phone]
Powerscourt Group
Sarah MacLeod / Nick Johnson / Sam Austrums / Ibrahim Khalil	[phone]

About Celadon Pharmaceuticals Plc

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility operates to an EU-GMP standard and comprises indoor hydroponic cultivation, proprietary GMP extraction and manufacturing and an analytical and R&D laboratory. The Company's subsidiary, LVL, owns a MHRA conditionally-approved clinical trial using cannabis based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics which is developing a licenced cannabinoid medicine to treat children with Autism Spectrum Disorder.

For further information please visit our website www.celadonpharma.com

 

END

 

 

DSHFLFISFIIILIV